A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: Effects of solvents and PLGA on drug release behaviors in vitro/in vivo

Journal of Materials Science: Materials in Medicine

Volumn 23, Issue 2, 2012, Pages 443-455

  Lin, Xia ^a   Yang, Shenshen ^a   Gou, Jingxin ^a   Zhao, Mingming ^a   Zhang, Yu ^a   Qi, Na ^a   He, Haibing ^a   Cai, Cuifang ^a   Tang, Xing ^a   Guo, Penghong ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BURST RELEASE; DELIVERY SYSTEMS; DRUG RELEASE; DRUG RELEASE MECHANISM; IN-SITU FORMING; IN-VITRO; IN-VIVO; MIXTURE MATRIX; RELEASE KINETICS; RISPERIDONE; SUSTAINED RELEASE;

SUGAR (SUCROSE);

DRUG PRODUCTS;

DIMETHYL SULFOXIDE; POLYGLACTIN; RISPERIDONE; SOLVENT; SUCROSE ACETATE ISOBUTYRATE;

AREA UNDER THE CURVE; ARTICLE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FLOW KINETICS; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; POROSITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; VISCOSITY;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY; DIFFUSION; DOPAMINE ANTAGONISTS; DRUG DELIVERY SYSTEMS; FEMALE; HYDROGEN-ION CONCENTRATION; KINETICS; LACTIC ACID; MALE; MICROSCOPY; OPTICS AND PHOTONICS; POLYGLYCOLIC ACID; POROSITY; RATS; RHEOLOGY; RISPERIDONE; SOLUBILITY; SOLVENTS; TIME FACTORS;

EID: 84862653239     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-011-4521-2     Document Type: Article

References (27)

1. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release. 2002;80:9-28.
2. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm. 2004;58:445-55.
3. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology. 2003;61:25-31.
4. Smith DA, Tipton AJ. A novel parenteral delivery system. Pharm Res. 1996;13:300.
5. Darling S, Okumu FW, Sullivan SA, Tipton AJ, Clealand JL. Extended release of human growth hormone suspended in Saber® formulation design and in vitro assessment. Proc Int Symp Control Rel Bioact Mater. 2001;28:474-5.
6. Kraeling RR, Barb CR, Rampacek GB, Thompson DL Jr, Gibson JW, Sullivan SA, et al. Luteinizing hormone response to con-trolled-release deslorelin in estradiol benzoate primed ovariec-tomized gilts. Theriogenology. 2000;53:1681-9.
7. Okumu FW, Dao le N, Fielder PJ, Dybdal N, Brooks D, Sane S, et al. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials. 2002;23:4353-8.
8. Gao Z, Ding P, Zhang L, Shi J, Yuan S, Wei J, et al. Study of a pingyangmycin delivery system: Zein/Zein-SAIB in situ gels. Int J Pharm. 2007;328:57-64.
9. Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL. Injectable controlled release formulations incorporating protein crystals. J Control Release. 2004;96:149-58.
10. Lu Y, Yu Y, Tang X. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci. 2007;96:3252-62.
11. Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Poly(ethyleneglycol) 500 dimethylether as novel solvent for injectable in situ forming depots. Pharm Res. 2009;26:2568-77.
12. Shively ML, Coonts BA, Renner WD, Southard JL, Bennett AT. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control Release. 1995;33:237-43.
13. Lu Y, Tang X, Cui Y, Zhang Y, Qin F, Lu X. In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. Eur J Pharm Biopharm. 2008;68:422-9.
14. M'Bareck CO, Nguyen QT, Metayer M, Saiter JM, Garda MR. Poly(acrylic acid) and poly(sodium styrenesulfonate) compati-bility by Fourier transform infrared and differential scanning calorimetry. Polymer. 2004;45:4181-7.
15. Zheng Q-Z, Wang P, Yang Y-N. Rheological and thermodynamic variation in polysulfone solution by PEG introduction and its effect on kinetics of membrane formation via phase-inversion process. J Memb Sci. 2006;279:230-7.
16. Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur J Pharm Sci. 2008;34:164-72.
17. Sathivel S, Huang J, Prinyawiwatkul W. Thermal properties and applications of the Arrhenius equation for evaluating viscosity and oxidation rates of unrefined pollock oil. J Food Eng. 2008; 84:187-93.
18. Graham PD, Brodbeck KJ, Mc Hugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release. 1999;58:233-45.
19. Martinsson A. On the composition of human adipose tissue. Acta Med Scand. 1967;182:795-803.
20. Higuchi WI. Analysis of data on the medicament release from ointments. J Pharm Sci. 1962;51:802-4.
21. Hutchinson FG, Furr BJA. Biodegradable carriers for the sus-tained release ofpolypeptides. Trends Biotechnol. 1987;5:102-6.
22. Ramchandani M, Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. J Control Release. 1998;54:167-75.
23. Shah SS, Cha Y, Pitt CG. Poly(glycolic acid-co-lactic acid): diffusion or degradation controlled drug delivery? J Control Release. 1992;18:261-70.
24. Tang Y, Singh J. Controlled delivery of aspirin: effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. Int J Pharm. 2008;357:119-25.
25. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woe-stenborghs R, Heykants J. Absorption, metabolism, and excre-tion of risperidone in humans. Drug Metab Dispos. 1993;21: 1134-41.
26. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-68.
27. Raman C, Mc Hugh AJ. A model for drug release from fast phase inverting injectable solutions. J Control Release. 2005;102: 145-57.